You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Integrating a suite of mental health apps for depression in a healthcare setting.

    SBC: Adaptive Health, Inc.            Topic: 104

    Abstract Depression is common, imposing a tremendous societal burden in terms of cost, morbidity, quality of life, and mortality. The great majority of people with depression are treated in primary care, however outcomes remain poor. There have been two broad attempts to address this problem. One is collaborative care, which uses care managers to coordinate patient care. Collaborative care can be ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Delivery system development for a reservoir targeted Lyme disease vaccine

    SBC: FoodSource Lure Corporation            Topic: NIAID

    DESCRIPTION (provided by applicant): The incidence and geographic distribution of Lyme disease in the U.S. has increased steadily since its first description in 1977. Efforts to stem the spread of the disease through controlling the population of its tickvector and/or the mouse reservoirs of the disease have met with only limited success. The only approved human vaccine to protect against Lyme di ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Improvement of Preclinical Oxygen Imager JIVA-25

    SBC: O2M TECHNOLOGIES LLC            Topic: NCI

    Abstract JIVA-25 is a small footprint 25 mT preclinical oxygen imager based on the principles of electron paramagnetic resonance oxygen imaging. JIVA-25 can provide oxygen maps in tissues with 1 mm spatial resolution, 1 torr oxygen resolution, and 1-10 min temporal resolution. No other competing method can provide accurate noninvasive pO2 maps with such precision. In tumors, accurate real-time pO2 ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Field Programmable Gate Array (FPGA) Physical Unclonable Functions

    SBC: Lewis Innovative Technologies, Inc.            Topic: OSD10A02

    LIT accomplished all Phase I goals and technical objectives. In Phase I LIT produced an effective Random Number Generator (RNG) and tested two PUF designs. The PUF designs showed greatly improved Entropy and Stability over other technologies. LITs Entropy Goal for Phase II is 100% (already proven by analysis) and the Stability goal is one bit error per million bits. In Phase II LIT will ma ...

    SBIR Phase II 2012 Department of DefenseOffice of the Secretary of Defense
  6. Developing a peptide-based oral drug to prevent kidney stones

    SBC: Oxalo Therapeutics, Inc.            Topic: 400

    Project Summary/Abstract Kidney stones (KS) are highly prevalent, excruciating, and associated with long term complications of chronic kidney disease (CKD) and end stage renal disease (ESRD). They account for 1.3M ER visits and andgt;$10B of medical costs annually and have a striking recurrence rate of 50% in 5 years and up to 80% in 10 years, reflecting the inadequacies of current interventions. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. First and Only Soft Tissue Support Device to Improve Patient Experience and System Cost in Breast Reconstruction

    SBC: Surgical Innovation Associates, Inc.            Topic: 102

    NOTE: These pages contain proprietary/privileged information. SIA requests that they not be released to personsoutside the Government, except for purposes of review and evaluation. Project Summary/Abstract DuraSorb™ is poised to significantly improve the lives of the over 100,000 US women undergoing post- mastectomy breast reconstruction every year. The current standard of care in implant-based ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Soluble high-affinity T cell receptors prevent MRSA lethality

    SBC: IMMUVEN, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Methicillin resistant Staphylococcus aureus (MRSA) and methicillin sensitive S. aureus (MSSA) are highly significant human health threats that are responsible for a range of diseases. Recently, the CDC and colleagues reported that MRSA are the most significant causes of serious infections and infectious disease deaths in the United States. A major factor involv ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. A single dose long-acting non-addictive polymer conjugate formulation of buprenorphine that provides immediate and prolonged analgesia for post-operative pain

    SBC: SERINA THERAPEUTICS INC            Topic: NINDS

    PAProject Summary Abstract SERis a long acting polymer pro drug of buprenorphine that is being developed to treat postoperative pain following major surgeries such as bunionectomyabdominoplastythoracotomy and knee and hip surgerySERhas no biological activity by itselfbut when administered in vivo by subcutaneous injection it enters the vascular compartment where a plasma esterasebutyrylcholinester ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. SampleStream: A Radically Simplified Platform for Protein Sample Preparation

    SBC: Integrated Protein Technologies, Inc.            Topic: 400

    Abstract: The rise of the global SARS-CoV-2 pandemic has exposed serious weaknesses in our ability to respond to novel pathogens. Three major areas of improvement include the rapid development of vaccines, therapeutics, and serosurveillence. All three of these areas require tools that accurately assess the immune response across individuals. Vaccine development requires lot-to-lot quality control ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government